Several studies have demonstrated that low-dose IL-2 therapy can successfully overcome Treg cell deficiency and increase the ratio of Treg to effector T cells in patients with RA and other autoimmune diseases [33,34,35]. This evidence concerns the gene IL2 and autoimmune disease.